|
|
|
|
This white paper examines the challenges of dsRNA in mRNA therapeutic safety and presents data on how Codex® HiCap RNA Polymerase boosts mRNA yields while reducing dsRNA byproducts.
|
|
|
|
|
As regulatory standards for mRNA vaccines and therapeutics tighten, we're exploring how Codex® HiCap RNA Polymerase improves capping efficiency, cuts costs, and streamlines IVT manufacturing.
|
|
|
|
|
Review the benefits of a co-transcriptional capping RNA polymerase engineered to produce synthetic RNA to meet these increasing demands for safety and cost-effectiveness.
|
|
|
|
|
Uncover how we were able to enhance RNA manufacturing with HiCap T7 RNA Polymerase, minimizing dsRNA, boosting expression, and reducing capping costs for superior therapeutic development.
|
|
|
|
|
|
|
|
|
|
|
